Archives
-
GSK-923295: A Strategic Lens on Mitotic Fidelity
2026-09-28
GSK-923295 offers a precise chemical approach to interrogating CENP-E-dependent chromosome alignment, mitotic checkpoint behavior, and translational vulnerabilities in cancer research. Its value extends beyond mitotic arrest: paired with emerging evidence on CTCF and centromere architecture, the compound can help researchers distinguish motor-driven congression defects from broader centromere-maintenance failures.
-
Oleanolic Acid, FXR, and Bile Acid Efflux Injury
2026-09-28
A 2024 study links oleanolic-acid-associated cholestatic liver injury with impaired bile-acid efflux, reduced tight-junction proteins, and altered FXR-related transporter function. Its combined transporter, tissue, and intervention findings provide a framework for investigating how bile acid handling and hepatocyte barrier integrity may contribute to liver injury.
-
Diclofenac in Human Intestinal Organoid Research
2026-09-27
Pair Diclofenac’s COX-inhibitory activity with human iPSC-derived intestinal models to study prostaglandin responses alongside epithelial drug-handling function. A staged workflow helps distinguish a genuine inflammation signal from solvent effects, loss of cell health, or unsupported assumptions about intestinal pharmacokinetics.
-
Latrunculin A for Actin Dynamics Workflows
2026-09-26
Use Latrunculin A to perturb actin assembly on a defined timescale, from rapid cytoskeleton disaggregation to longer exposure studies. This workflow connects dose and timing choices to a recent DRG axon-regeneration study while keeping the compound’s role distinct from the mechanosensitive pathway investigated there.
-
Oleanolic Acid, FXR, and Bile Acid Efflux Injury
2026-09-25
A 2024 study links oleanolic acid–associated liver injury to impaired bile acid efflux and weakened hepatocyte tight junctions, implicating FXR-regulated BSEP and MRP2. Its combination of in vivo and in vitro models, transporter-function measurements, and pharmacological perturbations offers a framework for studying cholestatic injury while leaving important questions about the sequence and specificity of these effects open.
-
GW4064: FXR Workflows for Metabolic Research
2026-09-25
Use GW4064 to test how FXR activation influences lipid regulation and liver-cell responses, including the FXR/TLR4/ferroptosis axis reported in a nanoparticle injury model. This workflow pairs potency-informed dose finding with practical guidance on solvent, light sensitivity, controls, and readout interpretation.
-
Angiotensin 1/2 (1-6): Beyond Vascular Signaling
2026-09-24
Angiotensin 1/2 (1-6) offers translational researchers a defined peptide for probing renin-angiotensin biology—and a way to investigate an emerging connection between angiotensin fragments and spike–AXL binding. This article separates established cardiovascular context from early in-vitro findings, then outlines a practical strategy for testing the fragment across assay systems.
-
GSK-923295 Workflows for CENP-E Biology
2026-09-24
Use GSK-923295 to perturb CENP-E directly and measure how impaired chromosome alignment reshapes mitotic progression. This workflow pairs dose-controlled cell assays with a useful contrast: recent CTCF findings point to centromere maintenance defects that are not simply equivalent to CENP-E inhibition.
-
PDK4-IN-1 Hydrochloride: Assay Workflows
2026-09-23
Build a practical PDK4-to-PDH workflow with concentration-ranging, phospho-PDH checks, and mitochondrial function readouts. The article separates product-reported properties from the published lead-compound evidence and offers troubleshooting guidance for metabolic, cardiac, and tumor-model research.
-
HBsAg–TBK1 Signaling in HBV Immune Evasion
2026-09-23
A 2025 Cell Death and Disease study identifies a mechanism in which hepatitis B surface antigen redirects TBK1 activity away from IRF3-dependent type I interferon production and toward p62-associated, incomplete autophagy. The work combines molecular interaction assays, pharmacological perturbation, animal models, and human liver samples to connect HBsAg-driven pathway reorganization with HBV persistence.
-
Sulfisomidine for Pertussis: Evidence and Methods
2026-09-22
The 1956 pertussis case series examined oral Sulfisomidine alongside hyperimmune pertussis serum in 21 hospitalized patients, emphasizing drug-level monitoring and early safety observations. Its findings suggest feasibility of achieving measurable blood concentrations, but the uncontrolled design and concurrent serum therapy limit conclusions about independent clinical efficacy.
-
GW4064: Reading FXR Signals Beyond Lipids
2026-09-22
GW4064 is a non-steroidal FXR agonist for dissecting bile acid, cholesterol, and triglyceride regulation. This article provides a decision-centered framework for connecting FXR activation in metabolic research with TLR4, ferroptosis, and collagen responses in hepatic stellate-cell models.
-
Necrostatin-1: A Mechanism-First Research Guide
2026-09-21
Necrostatin-1 is a selective RIP1 kinase inhibitor for dissecting necroptosis, inflammation, and tissue injury. This guide connects pharmacologic RIP1 blockade with viral RIPK3 regulation to improve assay interpretation and experimental design.
-
IR-820: From NIR Signal to Translational Insight
2026-09-21
IR-820, also known as New Indocyanine Green, can help translational researchers connect near-infrared fluorescence imaging with vascular and tumor biology. This thought-leadership review interprets the mechanistic lessons of a glutathione-responsive indocyanine green nanoplatform while defining a practical, evidence-aware workflow for evaluating IR-820 in preclinical imaging studies.
-
GW4064: Practical FXR Activation Workflows
2026-09-20
GW4064 is a selective non-steroidal FXR agonist for connecting receptor activation with bile acid transport, lipid regulation, and liver-injury phenotypes. This guide turns its potency and formulation constraints into practical assay workflows, controls, and troubleshooting decisions for metabolic research.